Assenagon Asset Management S.A. Purchases Shares of 111,568 Sienna Biopharmaceuticals Inc (SNNA)

Assenagon Asset Management S.A. purchased a new stake in shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 111,568 shares of the company’s stock, valued at approximately $1,653,000. Assenagon Asset Management S.A. owned 0.54% of Sienna Biopharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. BlackRock Inc. increased its holdings in Sienna Biopharmaceuticals by 10.6% during the 2nd quarter. BlackRock Inc. now owns 1,010,338 shares of the company’s stock valued at $15,348,000 after purchasing an additional 97,162 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Sienna Biopharmaceuticals by 4.2% during the 2nd quarter. Victory Capital Management Inc. now owns 489,890 shares of the company’s stock worth $7,442,000 after acquiring an additional 19,560 shares during the period. Northern Trust Corp grew its holdings in shares of Sienna Biopharmaceuticals by 17.7% during the 2nd quarter. Northern Trust Corp now owns 147,584 shares of the company’s stock worth $2,242,000 after acquiring an additional 22,146 shares during the period. Tiverton Asset Management LLC grew its holdings in shares of Sienna Biopharmaceuticals by 41.9% during the 2nd quarter. Tiverton Asset Management LLC now owns 78,031 shares of the company’s stock worth $1,185,000 after acquiring an additional 23,031 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Sienna Biopharmaceuticals by 15.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 36,945 shares of the company’s stock worth $561,000 after acquiring an additional 4,956 shares during the period. Institutional investors own 47.46% of the company’s stock.

SNNA stock opened at $10.05 on Friday. Sienna Biopharmaceuticals Inc has a fifty-two week low of $8.77 and a fifty-two week high of $25.71. The company has a current ratio of 5.82, a quick ratio of 5.82 and a debt-to-equity ratio of 0.54. The company has a market cap of $211.53 million, a price-to-earnings ratio of -1.94 and a beta of 1.48.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its earnings results on Thursday, November 8th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.03). On average, analysts expect that Sienna Biopharmaceuticals Inc will post -3.09 EPS for the current year.

SNNA has been the topic of a number of research analyst reports. BMO Capital Markets reduced their target price on Sienna Biopharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a report on Wednesday, August 1st. Zacks Investment Research downgraded Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 3rd.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/assenagon-asset-management-s-a-purchases-shares-of-111568-sienna-biopharmaceuticals-inc-snna.html.

Sienna Biopharmaceuticals Profile

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Featured Story: How accurate is the Rule of 72?

Institutional Ownership by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply